Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:CGC OTCMKTS:CHUC NYSE:MBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.96-2.6%$5.37$1.14▼$7.20$304.87M0.8774,038 shs796,478 shsCGCCanopy Growth$1.45+4.3%$1.30$0.77▼$5.80$333.39M0.7721.62 million shs18.67 million shsCHUCCharlie's$0.31-4.3%$0.18$0.03▼$0.35$85.29M0.9248,086 shs215,047 shsMBXMBX Biosciences$9.74-10.4%$12.98$4.81▼$27.50$327.21MN/A330,915 shs466,329 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-5.57%-10.70%-5.57%+64.72%-15.59%CGCCanopy Growth+1.46%+2.96%+6.92%+5.30%-70.98%CHUCCharlie's+6.91%+9.43%+66.50%+284.62%+261.11%MBXMBX Biosciences+0.37%-0.28%-26.15%+7.62%+1,086,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.96-2.6%$5.37$1.14▼$7.20$304.87M0.8774,038 shs796,478 shsCGCCanopy Growth$1.45+4.3%$1.30$0.77▼$5.80$333.39M0.7721.62 million shs18.67 million shsCHUCCharlie's$0.31-4.3%$0.18$0.03▼$0.35$85.29M0.9248,086 shs215,047 shsMBXMBX Biosciences$9.74-10.4%$12.98$4.81▼$27.50$327.21MN/A330,915 shs466,329 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-5.57%-10.70%-5.57%+64.72%-15.59%CGCCanopy Growth+1.46%+2.96%+6.92%+5.30%-70.98%CHUCCharlie's+6.91%+9.43%+66.50%+284.62%+261.11%MBXMBX Biosciences+0.37%-0.28%-26.15%+7.62%+1,086,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.67Moderate Buy$9.5089.43% UpsideCGCCanopy Growth 1.33SellN/AN/ACHUCCharlie's 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63276.06% UpsideCurrent Analyst Ratings BreakdownLatest CHUC, MBX, CGC, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025ALDXAldeyra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$1.19 per shareN/ACGCCanopy Growth$274.92M1.27N/AN/A$1.90 per share0.77CHUCCharlie's$8.49M9.84N/AN/A($0.01) per share-31.85MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$55.85M-$0.85N/AN/AN/AN/A-73.63%-50.61%11/6/2025 (Estimated)CGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)CHUCCharlie's-$4.16M$0.0131.88∞N/A19.36%-174.49%36.91%11/17/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ALatest CHUC, MBX, CGC, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CHUCCharlie'sN/A$0.02N/A$0.02N/A$2.54 million8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million8/7/2025Q2 2025ALDXAldeyra Therapeutics-$0.21-$0.16+$0.05-$0.16$1.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/ACHUCCharlie'sN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.862.86CGCCanopy Growth0.593.072.12CHUCCharlie's0.071.610.61MBXMBX BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CGCCanopy Growth3.33%CHUCCharlie's7.80%MBXMBX BiosciencesN/AInsider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics8.50%CGCCanopy Growth0.16%CHUCCharlie's20.90%MBXMBX Biosciences52.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1059.90 million54.81 millionOptionableCGCCanopy Growth3,150239.85 million239.47 millionOptionableCHUCCharlie's40262.43 million207.59 millionNot OptionableMBXMBX Biosciences3633.59 millionN/AN/ACHUC, MBX, CGC, and ALDX HeadlinesRecent News About These CompaniesWoodline Partners LP Has $6.48 Million Position in MBX Biosciences, Inc. $MBXSeptember 15 at 3:59 AM | marketbeat.com133,113 Shares in MBX Biosciences, Inc. $MBX Purchased by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comComparing MBX Biosciences (MBX) & Its RivalsSeptember 11, 2025 | americanbankingnews.comMBX Biosciences, Inc. $MBX Shares Acquired by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Given Consensus Rating of "Buy" by BrokeragesSeptember 8, 2025 | marketbeat.comWalleye Capital LLC Purchases New Position in MBX Biosciences, Inc. $MBXSeptember 7, 2025 | marketbeat.comJump Financial LLC Purchases Shares of 28,996 MBX Biosciences, Inc. $MBXSeptember 7, 2025 | marketbeat.comMBX Biosciences, Inc.: MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesitySeptember 6, 2025 | finanznachrichten.deMBX Biosciences doses first participant in Phase 1 trial of MBX 4291September 4, 2025 | msn.comMBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesitySeptember 4, 2025 | globenewswire.comMPM Bioimpact LLC Purchases Shares of 1,132,950 MBX Biosciences, Inc. $MBXSeptember 4, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys Shares of 175,000 MBX Biosciences, Inc. $MBXAugust 28, 2025 | marketbeat.comWellington Management Group LLP Sells 271,118 Shares of MBX Biosciences, Inc. $MBXAugust 28, 2025 | marketbeat.comMBX Biosciences Insiders Added US$579.8k Of Stock To Their HoldingsAugust 20, 2025 | uk.finance.yahoo.comMBX Biosciences Submits IND for Once-Monthly Obesity DrugAugust 20, 2025 | finance.yahoo.comJefferies Financial Group Initiates Coverage on MBX Biosciences (NYSE:MBX)August 17, 2025 | marketbeat.comA Glimpse of MBX Biosciences's Earnings PotentialAugust 14, 2025 | benzinga.comMBX Biosciences Reports Progress and Financial StabilityAugust 11, 2025 | tipranks.comMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 7, 2025 | globenewswire.comMizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationAugust 5, 2025 | msn.comMBX Biosciences Inc. (MBX) Stock Price Today - WSJAugust 2, 2025 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHUC, MBX, CGC, and ALDX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$4.96 -0.13 (-2.55%) Closing price 04:00 PM EasternExtended Trading$5.03 +0.07 (+1.31%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Canopy Growth NASDAQ:CGC$1.45 +0.06 (+4.32%) Closing price 04:00 PM EasternExtended Trading$1.47 +0.02 (+1.38%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Charlie's OTCMKTS:CHUC$0.31 -0.01 (-4.31%) As of 03:56 PM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.MBX Biosciences NYSE:MBX$9.74 -1.13 (-10.40%) Closing price 04:00 PM EasternExtended Trading$9.86 +0.12 (+1.23%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
